New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

The choice isn't that hard.

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Novo Nordisk and Eli Lilly have dominated the market until now, but this year is set to bring oral drugs, generics, and a ...

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an encouraging ...

Use of the diabetes drug Ozempic for weight loss is rising. Understand the research, how it works, who should use it, and ...

Novo Nordisk shares have surged on the back of its groundbreaking oral Wegovy approval, making it the first company to bring ...

Tonight’s digest tracks the accelerating use of trade and tariffs as geopolitical leverage, from Trump’s renewed pressure campaign over Greenland to Canada’s landmark trade reset with China. In the ...

Danish drugmaker Novo Nordisk's oral Wegovy (semaglutide) has recorded impressive early sales in the USA, and investors have ...

Oral semaglutide was approved by the FDA in December 2025 as a once-daily pill (25 mg), intended to limit excess body weight ...